Publications by authors named "R Y Nakata"
Background: The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies (ADTs), particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear.
Methods: This retrospective cohort analysis used data from the Medical Data Vision database, including patients with ulcerative colitis (UC) and Crohn's disease (CD) who had initiated UST therapy. Cumulative UST continuation rates and factors associated with UST failure were analyzed, and post hoc subgroup analyses based on prior ADT use were conducted.
Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis.
J Gastroenterol Hepatol
November 2024
Background And Aim: Tofacitinib and aminosalicylic acid (5-ASA) are commonly used to treat ulcerative colitis (UC). However, evidence on the effect of concomitant 5-ASA use in patients receiving tofacitinib is limited. This study investigated the effects of 5-ASA combined with tofacitinib in UC patients.
View Article and Find Full Text PDFUrinary collagen peptides, the breakdown products of endogenous collagen, have been used as biomarkers for various diseases. These non-invasive biomarkers are easily measured via mass spectrometry, aiding in diagnostics and therapy effectiveness. The objective of this study was to investigate the effects of consuming collagen-containing meat on collagen peptide composition in human blood and urine.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the risk of developing active tuberculosis (TB) in patients with Crohn's disease (CD) who are treated with various biologic therapies, focusing on TNF-α inhibitors compared to other biologics like ustekinumab (UST) and vedolizumab (VDZ).
- Researchers analyzed data from a large Japanese medical claims database, studying the association between biologic treatments and active TB occurrence across 28,811 patients, with a detailed assessment of treatment types and durations.
- The results indicated that TNF-α inhibitors significantly increase the risk of active TB, with none of the patients treated with UST or VDZ developing the infection, highlighting the safety of these alternatives for CD patients.